Get the Stockscreener App
3.05
1.29%
-0.04
After Hours:
3.01
-0.04
-1.31%
Savara Inc stock is traded at $3.05, with a volume of 1.67M.
It is down -1.29% in the last 24 hours and up +33.19% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.09
Open:
$3.09
24h Volume:
1.67M
Relative Volume:
1.09
Market Cap:
$527.15M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-9.2424
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+1.33%
1M Performance:
+33.19%
6M Performance:
+13.38%
1Y Performance:
-31.92%
1-Day Range:
$2.92
$3.18
1-Week Range:
$2.92
$3.28
52-Week Range:
$1.89
$4.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.05 | 527.15M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara publishes IMPALA-2 clinical trial results in NEJM - TipRanks
Savara’s autoimmune PAP treatment shows positive phase 3 results - Investing.com
9.8% Lung Function Improvement: Savara's Breakthrough PAP Treatment Succeeds in Largest-Ever Phase 3 Trial - Stock Titan
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Ariva
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 - MSN
Can Savara Inc. Escape Recent Bear Channel2025 Institutional Moves & AI Enhanced Trading Alerts - thegnnews.com
Savara Inc. shares fall 2.62% after-hours following the announcement of new data presentations at ERS Congress 2025. - AInvest
Savara partner to present data on dried blood spot test for aPAP diagnosis By Investing.com - Investing.com South Africa
Savara partner to present data on dried blood spot test for aPAP diagnosis - Investing.com
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 - DutchNews.nl
Major Phase 3 Data Coming: Savara's Breakthrough Treatment for Ultra-Rare Lung Disease aPAP at ERS 2025 - Stock Titan
Savara upgraded to Buy by H.C. Wainwright on potential Molbreevi marketing application resubmission. - AInvest
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
Savara Inc. Reports Increased Loss Amid Ongoing R&D Investments - MSN
What analysts say about Savara Inc. stockJuly 2025 Sentiment & Daily Oversold Stock Bounce Ideas - thegnnews.com
Savara Inc. (NASDAQ: SVRA): A Re-Rating Catalyst Unfolds as Clinical Progress and Analyst Upgrades Signal Long-Term Value - AInvest
Published on: 2025-08-16 20:17:05 - metal.it
Trendline Breach Raises Concern for Savara Inc. Investors2025 Trading Recap & Advanced Swing Trade Entry Alerts - metal.it
Savara Receives Analyst Upgrade and Price Target Increase - AInvest
Savara Upgraded to Buy by H.C. Wainwright Amid Resubmission Prospects - AInvest
H.C. Wainwright upgrades Savara to Buy on resubmission prospects - MSN
What makes Savara Inc. stock price move sharplyMarket Growth Report & Capital Efficient Trading Techniques - 선데이타임즈
Will Savara Inc. Recover After Recent DeclineTake Profit & Trade Opportunity Analysis Reports - 선데이타임즈
Savara stock upgraded at H.C. Wainwright (SVRA:NASDAQ) - Seeking Alpha
Savara Shares Rise After Upgrade From HC Wainwright - MarketScreener
Savara stock rating upgraded to Buy by H.C. Wainwright on BLA resubmission plans - Investing.com Australia
HC Wainwright Upgrades Savara to Buy From Neutral, $5 Price Target - MarketScreener
Oppenheimer raises Savara stock price target to $6 on BLA resubmission plans - Investing.com
Savara price target raised to $6 from $5 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Savara to $6 From $5, Maintains Outperform Rating - MarketScreener
Is There Enough Volume to Lift Savara Inc.2025 Big Picture & Weekly Market Pulse Alerts - newsyoung.net
Savara Posts Loss for Q2 2025 as Earnings Beat Fails to Drive Market Optimism - AInvest
HC Wainwright & Co. Upgrades Savara (SVRA) - MSN
Savara reports Q2 EPS (14c), consensus (12c) - MSN
Savara Inc.’s Price Action Aligns with Quant SignalsJuly 2025 Spike Watch & Free Community Supported Trade Ideas - sundaytimes.kr
Why Savara (SVRA.O) Spiked 14% Despite No Fresh News: A Technical and Market Flow Deep Dive - AInvest
Savara (SVRA.O) Surges 8.15% on Intraday Momentum – But No Technical or Order-Flow Confirmation - AInvest
More layoffs at Evotec; Savara to work with Fujifilm as manufacturing partner - Endpoints News
Savara Expects FDA Approval for Fujifilm-Manufactured Drug Substance in December - AInvest
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Savara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Bluefield Daily Telegraph
What machine learning models say about Savara Inc.Reversal Signal Prediction Based on Volume - Newser
Can a trend reversal in Savara Inc. lead to recoveryFree AI Based High Gain Watchlist Scanner - Newser
How Savara Inc. stock performs during market volatilityReal-Time Equity Price Action Analysis - Newser
Is Savara Inc. forming bullish engulfing patternsHigh Momentum Profit Stocks - thegnnews.com
Savara Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Why Savara Inc. stock attracts strong analyst attentionFree Conservative Long Term Growth Plans - Newser
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Is Savara Inc. stock overvalued or undervaluedSuperior capital gains - Jammu Links News
What are Savara Inc. company’s key revenue driversOverwhelming financial success - Jammu Links News
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):